Hyperparathyroidism, Primary: Clinical Trials

10 trials for Hyperparathyroidism, Primary, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 recruiting, 1 withdrawn. 10 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310Completed 8, Recruiting 1, Withdrawn 1
Phase 25Completed 3, Recruiting 1, Withdrawn 1

Follow Hyperparathyroidism, Primary: new trials by email Literature Review of Hyperparathyroidism, Primary trials Research Report on Hyperparathyroidism, Primary

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
18F-FCH, NeuroEXPLORER - Primary Hyperparathyroidism, Parathyroid Cancer
Phase 2 / Phase 3RecruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1932026-04-162026-06-02
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
18F-Fluorocholine, Positron emission tomography (PET) - Hyperparathyroidism, Primary
Phase 3CompletedThomas Hope1392021-06-302026-04-29
Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
KHK7580 - Parathyroid Carcinoma, Primary Hyperparathyroidism
Phase 3CompletedKyowa Kirin Co., Ltd.182017-08-302021-05-27
Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
Cinacalcet 30 mg Tablet, Denosumab Inj 60 mg/ml, Placebo tablets - Primary Hyperparathyroidism, Parathyroid Adenoma
Phase 3CompletedPeter Vestergaard462017-03-012021-05-25
18F-Fluorocholine for the Detection of Parathyroid Adenomas
18F-Fluorocholine, Positron Emission Tomography (PET) - Hyperparathyroidism, Primary
Phase 2 / Phase 3CompletedThomas Hope982016-09-212021-10-19
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
eplerenone, amiloride, Placebo - Primary Hyperparathyroidism
Phase 2 / Phase 3CompletedBrigham and Women's Hospital692016-01-012023-05-03
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
Cinacalcet HCl - Parathyroid Carcinoma, Hypercalcemia
Phase 3CompletedKyowa Kirin Co., Ltd.2011-11-012017-03-03
Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D
Placebo, Vitamin D3 - Primary Hyperparathyroidism, Hypercalcemia
Phase 2 / Phase 3WithdrawnColumbia University2010-05-012015-03-05
Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
Cinacalcet, Placebo - Hyperparathyroidism, Primary, Hypercalcemia
Phase 3CompletedAmgen672010-03-102018-10-17
Effect of Vitamin D Treatment in Primary Hyperparathyroidism
Cholecalciferol - Vitamin D Deficiency, Primary Hyperparathyroidism
Phase 2 / Phase 3CompletedUniversity of Aarhus462008-05-012013-11-18

Narrower conditions

Hypercalcemia (4)  ·  Parathyroid Neoplasms (4)  ·  Vitamin D Deficiency (2)  ·  Bone Diseases, Metabolic (1)  ·  Multiple Endocrine Neoplasia Type 1 (1)  ·  Osteoporosis (1)

Broader conditions

Endocrine System Diseases (10)  ·  Hyperparathyroidism (10)  ·  Parathyroid Diseases (10)  ·  Calcium Metabolism Disorders (4)  ·  Endocrine Gland Neoplasms (4)  ·  Head and Neck Neoplasms (4)  ·  Metabolic Diseases (4)  ·  Neoplasms (4)  ·  Neoplasms by Site (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Water-Electrolyte Imbalance (4)  ·  Avitaminosis (2)  ·  Deficiency Diseases (2)  ·  Malnutrition (2)  ·  Nutrition Disorders (2)

Interventions

Cinacalcet (4)  ·  fluorocholine (3)  ·  Cholecalciferol (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  Amiloride (1)  ·  Denosumab (1)  ·  Eplerenone (1)  ·  Sodium Chloride (1)  ·  Tablets (1)  ·  Vitamin D (1)  ·  evocalcet (1)

Sponsors

Kyowa Kirin Co., Ltd. (2)  ·  Thomas Hope (2)  ·  Amgen (1)  ·  Brigham and Women's Hospital (1)  ·  Columbia University (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Peter Vestergaard (1)  ·  University of Aarhus (1)

Countries

United States (6)  ·  Denmark (2)  ·  Japan (2)  ·  Australia (1)  ·  Canada (1)  ·  Hungary (1)  ·  Poland (1)  ·  Portugal (1)  ·  Russia (1)

Top investigators

Thomas Hope, MD (2)  ·  Anand Vaidya, MD MMSc (1)  ·  Julius Simoni Leere, MD (1)  ·  Lars Rejnmark, MD,PhD,DrMed (1)  ·  Lars Rolighed, MD (1)  ·  Peter Vestergaard, DMSc (1)  ·  Shonni J. Silverberg, MD (1)  ·  Smita Jha, M.D. (1)

Results publications

PMID 32333877, PMID 35018442

NIH funding

2016 (1), R01DK084986 (1)